278 related articles for article (PubMed ID: 8688084)
1. Cure of short- and long-term experimental Chagas' disease using D0870.
Urbina JA; Payares G; Molina J; Sanoja C; Liendo A; Lazardi K; Piras MM; Piras R; Perez N; Wincker P; Ryley JF
Science; 1996 Aug; 273(5277):969-71. PubMed ID: 8688084
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi.
Molina J; Brener Z; Romanha AJ; Urbina JA
J Antimicrob Chemother; 2000 Jul; 46(1):137-40. PubMed ID: 10882704
[TBL] [Abstract][Full Text] [Related]
3. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi.
Liendo A; Lazardi K; Urbina JA
J Antimicrob Chemother; 1998 Feb; 41(2):197-205. PubMed ID: 9533461
[TBL] [Abstract][Full Text] [Related]
4. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
[TBL] [Abstract][Full Text] [Related]
5. Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres.
Molina J; Urbina J; Gref R; Brener Z; Rodrigues Júnior JM
J Antimicrob Chemother; 2001 Jan; 47(1):101-4. PubMed ID: 11152439
[TBL] [Abstract][Full Text] [Related]
6. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
Urbina JA; Payares G; Contreras LM; Liendo A; Sanoja C; Molina J; Piras M; Piras R; Perez N; Wincker P; Loebenberg D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1771-7. PubMed ID: 9661019
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
9. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
[TBL] [Abstract][Full Text] [Related]
11. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
12. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease.
Araújo MS; Martins-Filho OA; Pereira ME; Brener Z
J Antimicrob Chemother; 2000 Jun; 45(6):819-24. PubMed ID: 10837436
[TBL] [Abstract][Full Text] [Related]
13. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
[TBL] [Abstract][Full Text] [Related]
14. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
16. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
Benaim G; Sanders JM; Garcia-Marchán Y; Colina C; Lira R; Caldera AR; Payares G; Sanoja C; Burgos JM; Leon-Rossell A; Concepcion JL; Schijman AG; Levin M; Oldfield E; Urbina JA
J Med Chem; 2006 Feb; 49(3):892-9. PubMed ID: 16451055
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Chagas' disease].
Apt W
Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
[No Abstract] [Full Text] [Related]
18. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
19. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
[TBL] [Abstract][Full Text] [Related]
20. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
Urbina JA
J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
